ReviewCurrent opinion in rheumatology2008
The interleukin-23/interleukin-17 axis in spondyloarthritis.
Review in Current opinion in rheumatology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 65 citations in OpenAlex.
- Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review.Frontiers in pharmacology · 2026Review
- RNA sequencing and bioinformatics analysis of differentially expressed genes in the peripheral serum of ankylosing spondylitis patients.Journal of orthopaedic surgery and research · 2023Article
- Genetic Background and Molecular Mechanisms of Juvenile Idiopathic Arthritis.International journal of molecular sciences · 2023Review
- No Significant Effects of IL-23 on Initiating and Perpetuating the Axial Spondyloarthritis: The Reasons for the Failure of IL-23 Inhibitors.Frontiers in immunology · 2022Review
- Article
- Recent Updates in Juvenile Spondyloarthritis.Rheumatic diseases clinics of North America · 2021Review
- Regeneration of Damaged Tendon-Bone Junctions (Entheses)-TAK1 as a Potential Node Factor.International journal of molecular sciences · 2020Review
- The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis.Nature reviews. Rheumatology · 2019Review
- Biological and genetic evaluation of IL-23/IL-17 pathway in ankylosing spondylitis patients.Central-European journal of immunology · 2019Article
- The synovio-entheseal complex in enthesoarthritis.Clinical and experimental medicine · 2016Review
- Focal bone involvement in inflammatory arthritis: the role of IL17.Rheumatology international · 2016Review
- Endoplasmic reticulum degradation-enhancing α-mannosidase-like protein 1 targets misfolded HLA-B27 dimers for endoplasmic reticulum-associated degradation.Arthritis & rheumatology (Hoboken, N.J.) · 2014Article
- An update on the contribution of the MHC to AS susceptibility.Clinical rheumatology · 2014Review
- Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond.Arthritis & rheumatology (Hoboken, N.J.) · 2014Review
- HLA-B27 misfolding and ankylosing spondylitis.Molecular immunology · 2014Review
- Update on juvenile spondyloarthritis.Rheumatic diseases clinics of North America · 2013Review
- How to translate basic knowledge into clinical application of biologic therapy in spondyloarthritis.Clinical & developmental immunology · 2013Review
- Expression of HLA-B27 causes loss of migratory dendritic cells in a rat model of spondylarthritis.Arthritis and rheumatism · 2012Article
- Increased plasma levels of IL-21 and IL-23 in spondyloarthritis are not associated with clinical and MRI findings.Rheumatology international · 2012Article
- ANTXR2 and IL-1R2 polymorphisms are not associated with ankylosing spondylitis in Chinese Han population.Rheumatology international · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewTo inform readers of recent advances in our understanding of the development and function of Th17 T cells and emerging data suggesting that the interleukin-23/interleukin-17 axis may be involved in the pathogenesis of spondyloarthritis. RECENT
findingsThe discovery of CD4+ Th17 T cells and the interleukin-23/interleukin-17 axis has challenged existing paradigms and the role of Th1 T cells in many autoimmune diseases. The development and cytokine profile of Th17 T cells differs in mice and humans. In humans, interleukin-23 synergizes with interleukin-6 and interleukin-1 to promote Th17 development. In mice, transforming growth factor-beta and interleukin-6 are critical, whereas interleukin-23 is more important at later stages promoting interleukin-17 production. In mice, CD4+ cells producing interferon-gamma appear to be distinct from interleukin-17-producing cells, while in humans cells secreting both cytokines have been observed. Growing evidence from animal models, cytokine analyses of patient fluids, and whole-genome association studies suggest that the interleukin-23/interleukin-17 axis plays an important role in spondyloarthritis pathogenesis. Possible links between an HLA-B27-induced unfolded protein response and activation of the interleukin-23/interleukin-17 axis have been observed in animal models and may contribute to the development of the spondyloarthritis phenotype. SUMMARY: Activation of the interleukin-23/interleukin-17 axis in spondyloarthritis has important therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.